WHY TETRA BIO-PHARMA?

Tetra Bio-Pharma Added to Leading Cannabis ETF:

Horizons Marijuana Life Sciences Index

• Only pharmaceutical company to have clinical studies for smoked marijuana
• Received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™ mucoadhesive product READ MORE
• Announced Health Canada's Green Light for the Cannabis vs. Fentanyl Trial READ MORE
• Announced FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
• PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy READ MORE
• Announces PPP002 Program Update Following Type B Meeting with U.S. FDA READ MORE
• One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products
• Health Canada Reclassifies Tetra Bio-Pharma’s Inhalation Device Making it Eligible for Reimbursement READ MORE
• Tetra Successfully Completes Phase 1 Study With Vaporized Version of PPP001 Read More

Company Interviews

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

• Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.

• 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

• A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
• Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
• Pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

12 Month Stock Chart